OV
OVID.US Ovid Therapeutics Inc
- Market cap
- USD 479M
- P/E
- -
- P/B
- 2.41x
- ROE
- -35.4%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is OVID.US undervalued?
Graham numberThe Graham number of Ovid Therapeutics Inc cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Ovid Therapeutics Inc fundamental analysis
No fundamental analysis for Ovid Therapeutics Inc yet.
Ovid Therapeutics Inc stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Ovid Therapeutics Inc
Ovid Therapeutics Inc., a biopharmaceutical company, engages in the development of small molecule medicines for brain disorders including epilepsies and seizure-related neurological disorders in the United States. The company is developing OV329, a GABA-AT inhibitor which is in Phase 1 clinical trials for the treatment of adult and infant drug-resistant epilepsies; and OV4071, a first-in-human oral potassium-chloride cotransporter 2 direct activator which is in Phase 1 clini…
Full company profileOvid Therapeutics Inc financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Ovid Therapeutics Inc annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 12.6M | 208M | 1.50M | 392K | 566K | 7.25M | 977K |
| Gross Profit | -56.5K | -80.3K | -142K | -255K | 12.6M | 208M | 1.50M | 392K | 566K | 6.95M | - |
| Operating Income | -22.5M | -65.0M | -52.9M | -61.4M | -81.4M | 124M | -55.5M | -59.3M | -61.9M | -42.4M | -74.5M |
| EBITDA | -22.5M | -64.9M | -52.8M | -61.2M | -81.1M | 124M | -54.2M | -57.0M | -57.8M | -17.1M | -71.5M |
| Net Income | -22.4M | -64.8M | -52.0M | -59.3M | -80.7M | 123M | -51.4M | -52.3M | -26.4M | -17.4M | -70.4M |
| EPS | -1.14 | -3.35 | -2.11 | -1.51 | -1.38 | 1.80 | -0.73 | -0.74 | -0.37 | -0.24 | -0.35 |
| Balance Sheet | |||||||||||
| Total Assets | 53.0M | 89.5M | 47.6M | 80.8M | 75.9M | 195M | 155M | 144M | 92.2M | 151M | 222M |
| Total Liabilities | 3.73M | 6.02M | 8.84M | 10.8M | 32.3M | 14.8M | 23.0M | 56.2M | 23.9M | 20.3M | 23.6M |
| Shareholders' Equity | 49.3M | 83.4M | 38.8M | 70.0M | 43.6M | 180M | 132M | 87.8M | 68.2M | 131M | 199M |
| Cash & Short-term Investments | 51.9M | 87.1M | 41.5M | 76.7M | 72.0M | 188M | 129M | 106M | 53.1M | 69.6M | 137M |
| Total Debt | - | - | - | - | - | - | 16.5M | 16.0M | 14.8M | 13.4M | 12.4M |
| Cash Flow | |||||||||||
| Operating Cash Flow | -17.8M | -31.5M | -45.6M | -51.1M | -51.6M | 119M | -55.2M | -45.8M | -56.0M | -38.3M | -63.2M |
| Capital Expenditure | 189K | 47.4K | 352K | 244K | 391K | 189K | 1.42M | 137K | 71.0K | 0.00 | 0.00 |
| Free Cash Flow | -18.0M | -31.5M | -45.9M | -51.3M | -52.0M | 118M | -56.6M | -45.9M | -56.0M | -38.3M | -63.2M |
| Ratios | |||||||||||
| ROE | -45.5% | -77.7% | -134.0% | -84.6% | -185.0% | 68.3% | -38.9% | -59.6% | -38.7% | -13.3% | -35.4% |
| ROA | -42.3% | -72.4% | -109.1% | -73.3% | -106.3% | 63.1% | -33.1% | -36.3% | -28.7% | -11.5% | -31.7% |
| Net Profit Margin | - | - | - | - | -639.8% | 58.9% | -3,421.0% | -13,351.8% | -4,670.1% | -240.1% | -7,200.1% |
| Debt to Equity | - | - | - | - | - | - | 0.13x | 0.18x | 0.22x | 0.10x | 0.06x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Ovid Therapeutics Inc dividends
Ovid Therapeutics Inc has not paid dividends in the last 9 fiscal years.
Who owns Ovid Therapeutics Inc
- Insiders 7.34%
- Institutions 85.95%
- Public & others 6.72%
- Shares outstanding 189M
- Free float 157M
Top funds holding OVID.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Eventide Healthcare & Life Sciences I | 11.8M | 6.26% | +19.11% | Jun 2026 |
| Federated Hermes Kaufmann Small Cap A | 5.95M | 3.15% | 0.00% | Sep 2026 |
| Vanguard MStar Total Stk Mkt Idx Invest | 5.65M | 3.00% | 0.00% | Sep 2026 |
| iShares Russell 2000 ETF | 4.11M | 2.18% | 0.00% | Oct 2026 |
| State Street® SPDR® S&P® Biotech ETF | 2.98M | 1.58% | +2.69% | Oct 2026 |
| Fidelity Small Cap Index | 1.68M | 0.89% | 0.00% | Aug 2026 |
| iShares Russell 2000 Value ETF | 1.35M | 0.71% | 0.00% | Oct 2026 |
| Vanguard Russell 2000 ETF | 960K | 0.51% | +9.19% | Sep 2026 |
| Fidelity Extended Market Index | 835K | 0.44% | +0.02% | Sep 2026 |
| Biotech Growth Ord | 747K | 0.40% | 0.00% | Jul 2026 |
| Nuveen Equity Index R6 | 647K | 0.34% | 0.00% | Sep 2026 |
| Vanguard US Momentum Factor ETF | 540K | 0.29% | 0.00% | Sep 2026 |
| Fidelity Enhanced Small Cap Core ETF | 531K | 0.28% | +0.27% | Oct 2026 |
| iShares Micro-Cap ETF | 500K | 0.27% | 0.00% | Oct 2026 |
| Schwab Small Cap Index | 401K | 0.21% | +7.81% | Sep 2026 |
| Fidelity Total Market Index | 348K | 0.18% | -0.05% | Sep 2026 |
| iShares Core S&P Total US Stock Mkt ETF | 344K | 0.18% | +0.03% | Oct 2026 |
| iShares Russell 2000 Small-Cap Idx Instl | 308K | 0.16% | +7.49% | Sep 2026 |
| Avantis US Small Cap Equity ETF | 271K | 0.14% | +0.24% | Oct 2026 |
| Fidelity Series Total Market Index | 263K | 0.14% | 0.00% | Sep 2026 |
Top institutions holding OVID.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Jupiter Topco LLC | 20.7M | 10.99% | 0.00% | Jun 2026 |
| Eventide Asset Management, LLC | 11.8M | 6.26% | +19.11% | Jun 2026 |
| BlackRock Inc | 10.8M | 5.74% | +605.90% | Jun 2026 |
| RA Capital Management, LLC | 10.5M | 5.56% | -1.99% | Jun 2026 |
| Affinity Asset Advisors, LLC | 10.1M | 5.38% | -4.62% | Jun 2026 |
| State Street Corp | 7.90M | 4.19% | +1,418.55% | Jun 2026 |
| Vanguard Capital Management, LLC | 7.76M | 4.11% | +47.58% | Jun 2026 |
| ADAR1 Capital Management LLC | 7.42M | 3.93% | +63.23% | Jun 2026 |
| Balyasny Asset Management LLC | 6.72M | 3.56% | +21.43% | Jun 2026 |
| Adage Capital Partners Gp LLC | 6.16M | 3.27% | 0.00% | Jun 2026 |
| Federated Hermes Inc | 5.95M | 3.15% | +66.67% | Jun 2026 |
| BRAIDWELL LP | 5.92M | 3.14% | 0.00% | Jun 2026 |
| Geode Capital Management, LLC | 4.07M | 2.16% | +208.98% | Jun 2026 |
| SILVERARC CAPITAL MANAGEMENT, LLC | 3.10M | 1.64% | +210.11% | Jun 2026 |
| StemPoint Capital LP | 2.42M | 1.28% | 0.00% | Jun 2026 |
| Ikarian Capital, LLC | 2.27M | 1.20% | -21.59% | Jun 2026 |
| Point72 Asset Management, L.P. | 1.95M | 1.03% | +47.34% | Jun 2026 |
| Sphera Funds Management Ltd. | 1.35M | 0.72% | -16.63% | Jun 2026 |
| Northern Trust Corp | 1.25M | 0.66% | +389.06% | Jun 2026 |
| Vanguard Fiduciary Trust Co | 1.14M | 0.60% | +64.55% | Jun 2026 |
Ovid Therapeutics Inc company profile
- Company name
- Ovid Therapeutics Inc
- Ticker
- OVID.US
- Exchange
- USA Stocks
- Listed since
- May 5, 2017
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 23
- Fiscal year end
- December
- Address
- Hudson Commons, New York, NY, United States, 10001
- Phone
- 646 661 7661
- Website
- ovidrx.com
About Ovid Therapeutics Inc
Ovid Therapeutics Inc., a biopharmaceutical company, engages in the development of small molecule medicines for brain disorders including epilepsies and seizure-related neurological disorders in the United States. The company is developing OV329, a GABA-AT inhibitor which is in Phase 1 clinical trials for the treatment of adult and infant drug-resistant epilepsies; and OV4071, a first-in-human oral potassium-chloride cotransporter 2 direct activator which is in Phase 1 clinical trials for the treatment of psychosis associated with parkinson's disease, lewy body dementia, and acute schizophrenia. It has license and collaboration agreements with AstraZeneca AB, H. Lundbeck A/S, Northwestern University, and Graviton, as well as Marinus Pharmaceuticals, Inc. The company was incorporated in 2014 and is headquartered in New York, New York.
Ovid Therapeutics Inc management
10- Dr. Jeremy Max Levin Ba Zoology, Dphil, M.D., Mb Bchir, Ph.D.Co-Founder & Executive Chairman · born 1953
- Ms. Margaret AlexanderCEO, President & Director · born 1981
- Mr. Jeffrey A. RonaAdvisor · born 1968
- Mr. Charles Ross Carter M.B.A., M.S.CFO, Principal Financial Officer, Principal Accounting Officer & Secretary · born 1967
- Dr. Zhong Zhong Ph.D.Chief Scientific Officer
- Dr. Julia Tsai Ph.D.Senior Vice President of Clinical Development · born 1975
- Dr. Toshiya Nishi D.V.M.Head of Epilepsy Research
- Ms. Victoria FortChief Strategy Officer
- Dr. Petra Kaufmann M.D., M.S.Chief Medical Officer · born 1966
- Mr. Kevin Norrett M.B.A., M.S.Chief Business Officer · born 1973